Skip to main content
Clinical Trials/CTRI/2018/01/011403
CTRI/2018/01/011403
Completed
Phase 4

Evaluation of â??Quality of Lifeâ?? and in-use tolerance in women with facial melasma, after using a triple combination drug (TRI-LUMA Cream)

Galderma India Private Limited0 sites33 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Galderma India Private Limited
Enrollment
33
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 19, 2018
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Participants with moderate to severe melasma on the face.
  • Childbearing potential patient with highly effective contraceptive methods
  • Willing to avoid unusual sun exposure as far as possible for the entire study duration.

Exclusion Criteria

  • Patients with prior history of mometasone based triple combination melasma therapy or under hormonal replacement therapy including usage of OC pills
  • If Patients were immunocompromised or were under immunosuppressive treatment, or had contraindications for corticosteroid treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials